Tags : BioInvent

PharmaShots Weekly Snapshot (Jun 22- 26, 2020)

 1.  EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s Forsteo (teriparatide) for the Treatment of Osteoporosis Published: Jun 26, 2020 | Tags: EMA, CHMP, Recommend, Approval, Two, Biosimilar, Referencing, Lilly, Forsteo, teriparatide, Osteoporosis 2.  Medtronic Receives the US FDA’s Approval for its Percept PC Neurostimulator with BrainSense Technology Published: Jun 25, 2020 | Tags: Medtronic, […]Read More

BioInvent Reports the Enrollment of First Patient in P-I/IIa Study

Shots: The focus of the study is to evaluate safety and tolerability profile of the combination of BI-1206 with Keytruda, characterizing PK/PD profile and to determine the recommended dose of the combination regimen The study is divided into two parts into Part A, a dose escalation of BI-1206 in combination with the standard dose of […]Read More

PharmaShots Weekly Snapshot (December 23-27, 2019)

1. Luye Pharma Reports Submission of NDA to the US FDA for LY03005 Published: Dec 26, 2019 | Tags: FDA, Luye Pharma, LY03005, NDA, reports, Submission, US 2. Immunomedics Reports the US FDA’s Acceptance of BLA for Sacituzumab Govitecan to Treat Metastatic Triple-Negative Breast Cancer Published: Dec 26, 2019 | Tags: Acceptance, BLA, FDA, Immunomedics, […]Read More

Pfizer Extends its Research and License Agreement with BioInvent to

Shots: Pfizer has selected its second target under the research and license agreement signed by the companies in 2016 and has extended the research term by six months BioInvent to receive $0.3M as target fees and will get milestones for the development of Ab directed against the target and is eligible to receive further milestones […]Read More

BioInvent Collaborates with MSD to Evaluate BI-1206 in Combination with

Shots: The companies collaborate to evaluate the combination of BioInvent’s BI-1206 and MSD’s Keytruda in a P-l/lla clinical study for patients with solid tumors, prior treated with anti-PD-1 or anti-PD-L1 Ab The collaboration allows BioInvent to expand the clinical development of BI-1206 against solid tumors. The preclinical data demonstrated that BI-1206 addresses the mechanism of […]Read More

PharmaShots Weekly Snapshot (August 19 – 23, 2019)

OxThera’s Oxabact Receives EMA’s Positive Decision on Pediatric Investigational Plan to Treat Primary Hyperoxaluria Published: Aug 23, 2019 | Tags: OxThera, Oxabact, Receives, EMA, Positive Decision, Pediatric Investigational Plan, Treat, Primary Hyperoxaluria 2.Novartis Signs an Option Agreement with Iconic Therapeutics for its Ophthalmology Program Published: Aug 22, 2019 | Tags: Novartis, Signs, Option Agreement, Iconic Therapeutics, Ophthalmology […]Read More

BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with

Shots: In July’2019, Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor, prior treated with anti-PD1 […]Read More